

20060615-07
AP20 Rec'd PCT/PTO 15 JUN 2006
CASE 33510-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

BRUEMMENDORF ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP2004/014439

FILED: 17 DECEMBER 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: COMBINATION OF (A) N-{5-[4-(4-METHYL-IPERAZINO-METHYL)-
BENZOYLAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-
PYRIMIDINE-AMINE AND (B) AT LEAST ONE HYPSINATION
INHIBITOR AND THE USE THEREOF

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/014439, copies are not enclosed herewith.

10/583107

100-04947-15 JUN 2006

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,



Oona A. Jackson
Attorney for Applicants
Reg. No. 48,152

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7852

Date: June 15, 2006

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 1 of 3
107583107

ATTY. DOCKET NO.
33510-US-PAT
APPLICATION NO.
Not Yet Known
APPLICANT
BRUEMMENDORF ET AL.
FILING DATE
Herewith

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	6,465,504	10/15/02	Lattmann et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AM	0 227 593	7/1/87	EP			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/007676	1/22/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	O'Dwyer et al., "Preliminary evaluation of the combination of imatinib mesylate (Gleevec) in combination with low dose interferon-alpha for the treatment of chronic phase CML," Blood, Vol. 98(11), p. 846A (2001)
AS	Quejada et al., Blood, Vol. 98(11), p. 370B (2001)
AT	Rosee et al., "Insights from pre-clinical studies for new combination treatment regimens with the BCR-ABL kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: A translational perspective" Leukemia, Vol. 16(7), pp. 1213-1219 (2002)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 2 of 3
ATTY. DOCKET NO. 33510-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
BRUEMMENDORF ET AL.FILING DATE
AP20R000001PTO 15 JUN 2006
Review

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
BA						
BB						
BC						
BD						
BE						
BF						
BG						
BH						
BI						
BJ						
BK						
BL						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
BM						<input type="checkbox"/>	<input type="checkbox"/>
BN						<input type="checkbox"/>	<input type="checkbox"/>
BO						<input type="checkbox"/>	<input type="checkbox"/>
BP						<input type="checkbox"/>	<input type="checkbox"/>
BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BR	Topaly et al., "Synergistic activity of the new ABL-specific tyrosine kinase inhibitor ST1571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells," Leukemia, Vol. 15(2001), pp. 342-347 (2001)
BS	Rosee et al., "Preclinical evaluation of the efficacy of ST1 in combination with a variety of novel anticancer agents," Blood, Vol. 98(11), Part 1, p. 839A (2001)
BT	Jansson et al., "Cell cycle arrest in archaea by the hypusination inhibitor N1-guanyl-1,7-diaminoheptane," Journal of Bacteriology, Vol. 182(4), pp. 1158-1161 (2000)

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Sheet 3 of 3
10/583107
ATTY. DOCKET NO.
33510-US-PO
APPLICATION NO.
Not Yet Known
APPLICANT
BRUEMMENDORF ET AL.
FILING DATE
Herewith

Group
10/583107
25 JUN 2000

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA						
	BB						
	BC						
	BD						
	BE						
	BF						
	BG						
	BH						
	BI						
	BJ						
	BK						
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
	BM						<input type="checkbox"/> <input checked="" type="checkbox"/>
	BN						<input type="checkbox"/> <input checked="" type="checkbox"/>
	BO						<input type="checkbox"/> <input checked="" type="checkbox"/>
	BP						<input type="checkbox"/> <input checked="" type="checkbox"/>
	BQ						<input type="checkbox"/> <input checked="" type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

BR	Caraglia et al., "Post-translational modifications of eukaryotic initiation factor-5A (eIF-5A) as a new target for anti-cancer therapy," Advances in Experimental Medicine and Biology, Vol. 472, pp. 187-198 (2000)
BS	
BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.